Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advaxis wins FDA approval for Phase II CIN trial
Advaxis has submitted its investigational new drug (IND) application to the FDA in May 2008, which outlined the proposed protocol for a Phase II clinical trial safety study
Advaxis has submitted its investigational new drug (IND) application to the FDA in May 2008, which outlined the proposed protocol for a Phase II clinical trial safety study
AM211 is an oral, selective antagonist of the receptor DP2 (also known as CRTH2 or chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes). DP2 is a high affinity receptor
BioSante has received $3.32 million on signing with Azur, of which approximately $1.5 million was purchased inventory. Antares is entitled to 25% of any upfront and milestone payments
arGentis anticipates the confirmation process by the European Commission should be finalized in early 2009. Once confirmed, arGentis subsidiary, arGentis Autoimmune Europe, will gain access to incentives including
The Culex automated in vivo sampling system is designed to collect pharmacokinetic and pharmacodynamic (PK/PD) data during the course of drug metabolism experiments. The Culex systems can collect
Under the terms of the agreement, BioMarin will receive a co-exclusive license to develop and commercialize Riquent and La Jolla could receive up to $289 million in cash
The Phase I clinical trial is an open label, dose determination study which will be conducted in the US with approximately 24 hemodialysis patients in two treatment cohorts.
Robert Thomas, chairman of board of directors of Concentric Medical, said: “The positive developments at Concentric over the last several months made the opportunity to participate in this
Prior to joining Bristol-Myers Squibb, Dr Feldman served as professor and head of the division of neurology at University of British Columbia and Vancouver Coastal Health, Vancouver, Canada.
Applications similar to these patents are pending worldwide, and several additional applications that address other compositions and uses have been filed in the US and other territories. These